What is the recommended dose adjustment of cefixime (Cefixime) for patients with stage 3 renal disease (Impaired renal function)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 20, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Cefixime Dosing in Stage 3 Chronic Kidney Disease

For patients with stage 3 CKD (creatinine clearance 21-59 mL/min), reduce cefixime to 260 mg daily (13 mL of the 100 mg/5 mL suspension or 6.5 mL of the 200 mg/5 mL suspension). 1

Dosing Algorithm by Renal Function

Stage 3A CKD (CrCl 45-59 mL/min)

  • Dose: 260 mg once daily 1
  • Use 13 mL of 100 mg/5 mL suspension OR 6.5 mL of 200 mg/5 mL suspension 1
  • The 200 mg/5 mL concentration is preferred for ease of administration 1

Stage 3B CKD (CrCl 30-44 mL/min)

  • Dose: 260 mg once daily 1
  • Same dosing as Stage 3A, as FDA labeling groups CrCl 21-59 mL/min together 1

Severe Renal Impairment (CrCl <30 mL/min)

  • Dose: 172 mg once daily 1
  • Use 8.6 mL of 100 mg/5 mL suspension OR 4.4 mL of 200 mg/5 mL suspension 1

Pharmacokinetic Rationale

The elimination half-life of cefixime increases from 3.7 hours in normal renal function to 12-14 hours when creatinine clearance falls below 20 mL/min. 2

  • Peak serum concentrations (Cmax) are slightly elevated in renal impairment, reaching 2.27 mcg/mL at 8 hours (versus 2.50 mcg/mL at 2.83 hours in normal function) 2, 3
  • Total body clearance decreases proportionally with declining creatinine clearance 2
  • Only 40% of cefixime is renally excreted, with 60% undergoing hepatic clearance, which explains why dose reduction is less dramatic than with purely renally-cleared drugs 4, 5

Critical Safety Considerations

Neurotoxicity Risk

Beta-lactam antibiotics including cephalosporins can cause neurotoxicity in renal impairment, even with appropriate dose adjustments. 6, 7

  • Monitor for confusion, encephalopathy, myoclonus, seizures, and status epilepticus 6, 7
  • Cefixime has lower pro-convulsive activity compared to other cephalosporins like cefepime, but vigilance remains essential 6
  • Neurotoxicity risk is particularly elevated in patients with chronic kidney disease 7

Dialysis Considerations

Neither hemodialysis nor peritoneal dialysis removes significant amounts of cefixime from the body. 1

  • For hemodialysis patients: Use the 260 mg daily dose (same as CrCl 21-59 mL/min) 1
  • No supplemental post-dialysis dose is required 1
  • Timing of administration relative to dialysis is not critical given minimal drug removal 1

Practical Administration Points

Cefixime can be administered without regard to food, as meals do not affect absorption or peak concentrations. 4

  • After reconstitution, suspension remains stable for 14 days at room temperature or refrigerated 1
  • Shake well before each use 1
  • For Streptococcus pyogenes infections, continue treatment for at least 10 days regardless of renal function 1

Common Pitfall to Avoid

Do not use normal dosing (400 mg daily) in stage 3 CKD. The FDA label explicitly requires dose reduction when creatinine clearance is below 60 mL/min 1. Research demonstrates that failure to adjust dosing results in drug accumulation, with serum levels remaining elevated (0.99 mcg/mL at 24 hours in severe renal impairment versus 0.10 mcg/mL in normal function) 3. This accumulation increases the risk of adverse effects, particularly neurotoxicity 6, 7.

References

Research

Relationship between renal function and disposition of oral cefixime.

European journal of clinical pharmacology, 1991

Research

[Pharmacokinetics of cefixime in patients with impaired renal function].

The Japanese journal of antibiotics, 1986

Research

[Pharmacokinetic properties of cefixime].

Presse medicale (Paris, France : 1983), 1989

Guideline

Cefixime Dosage Adjustment in Renal Impairment

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.